Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million
Key Points
The CEO liquidated 4,669 shares at a price of $320.37 per share, totaling ~$1.5 million on August 11, 2026.
The transaction resulted in a 4% reduction of the executive's total equity holdings in the company.
Schechter maintains a direct ownership position of 102,565 shares.
The disposition was executed under a Rule 10b5-1 trading plan, characterizing the move as a pre-scheduled liquidity event.
- 10 stocks we like better than Labcorp Holdings Inc. ›
Adam H. Schechter, President & CEO, sold 4,669 shares of Labcorp Holdings Inc. (NYSE:LH) for approximately $1.5 million on Aug. 11, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (directly held) | 4,669 |
| Transaction value | $1.5 million |
| Post-transaction shares (directly held) | 102,565 |
| Post-transaction value | $33 million |
Transaction value based on SEC Form 4 weighted average sale price ($320.37); post-transaction value based on Aug. 11, 2026, market close ($322.42).
Key questions
- What was the mechanism governing this sale?
The transaction was executed under a Rule 10b5-1 plan, which allows insiders to set a predetermined schedule for selling shares to meet liquidity or diversification needs while complying with insider trading regulations. - What is the scale of the CEO's remaining equity interest?
Schechter continues to hold 102,565 shares directly, representing a market valuation of $33 million as of the Aug. 11, 2026, market close. - How has the equity performed relative to this transaction?
Shares of the medical diagnostics company realized a 21% total return over the 12 months concluding on the Aug. 11, 2026, transaction date. - What does the trade indicate about insider sentiment?
Given that the sale represented approximtely 4% of Schechter's direct holdings and was executed via a Rule 10b5-1 plan, the activity reflects routine portfolio management rather than a discretionary change in outlook.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-11) | $322.42 |
| Market Capitalization | $26.4 billion |
| Revenue (TTM) | $14.3 billion |
| Net Income (TTM) | $1.0 billion |
Company Snapshot
- Labcorp Holdings provides comprehensive diagnostic laboratory services, including clinical testing, drug development support, and scientific research capabilities, generating revenue from healthcare facilities, pharmaceutical companies, medical professionals, and patients.
- The company operates a centralized laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers while generating revenue through testing fees, volume-based contracts, and pharmaceutical research partnerships.
- Labcorp serves a diverse customer base, including hospitals, physician practices, pharmaceutical firms conducting clinical trials, employers offering occupational health services, and individual patients seeking diagnostic testing.
Labcorp Holdings is one of the largest clinical laboratory networks in the United States, with 71,000 employees and a market capitalization of $26.4 billion. The company leverages its extensive laboratory infrastructure and technological capabilities to maintain a competitive position in the diagnostics market, supported by strong financial performance with TTM revenue of $14.3 billion and net income of $1.0 billion.
Labcorp's diversified customer base and integrated service offerings across clinical diagnostics, drug development, and occupational health provide multiple revenue streams and operational resilience.
What this transaction means for investors
This sale shouldn’t concern investors, as it represented a small percentage of the executive’s holdings. Moreover, it was completed under a Rule 10b5-1 plan. Insiders often use this to execute pre-planned transactions to avoid appearing to act on any material non-public information.
Importantly, Labcorp’s business continues to perform well. TTM revenue grew 6.4% year over year. Margins are on the rise, with operating profit surging 25% on a trailing basis. The growth reflects solid performance from the diagnostics segment and a recovery in the company’s biopharma lab services business.
Following its recent quarterly results, management raised its full-year guidance reflecting operating momentum. Analysts expect the company to grow 20% annually over the next two years, while the stock trades at a modest forward price-to-earnings multiple of 17x.
Should you buy stock in Labcorp Holdings Inc. right now?
Before you buy stock in Labcorp Holdings Inc., consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Labcorp Holdings Inc. wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $403,337!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,334,946!*
Now, it’s worth noting Stock Advisor’s total average return is 958% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 12, 2026.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
